GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

KPC Pharmaceuticals 600422.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.70

-1.81%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.58bn

FY2016FY2025

Net income

CN¥349.9m

FY2016FY2025

Free cash flow

CN¥198.7m

FY2016FY2025

Shareholders' equity

CN¥5.36bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥6.58bnCN¥8.40bnCN¥8.43bnCN¥8.28bnCN¥8.25bnCN¥7.72bnCN¥8.12bnCN¥7.10bnCN¥5.85bnCN¥5.10bn
Gross profitCN¥2.53bnCN¥3.63bnCN¥3.89bnCN¥3.43bnCN¥3.39bnCN¥3.31bnCN¥3.94bnCN¥3.54bnCN¥2.63bnCN¥1.97bn
Research and developmentCN¥102.5mCN¥106.8mCN¥94.2mCN¥69.7mCN¥100.5mCN¥128.4mCN¥83.5mCN¥82.7mCN¥117.2mCN¥99.2m
Operating incomeCN¥473.6mCN¥940.4mCN¥789.7mCN¥497.1mCN¥634.0mCN¥540.8mCN¥577.7mCN¥419.8mCN¥411.9mCN¥444.2m
Net incomeCN¥349.9mCN¥648.1mCN¥540.7mCN¥383.2mCN¥507.7mCN¥456.9mCN¥454.3mCN¥335.5mCN¥330.1mCN¥407.3m
Diluted earnings per share0.440.870.700.530.670.600.600.470.430.52

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥11.77bnCN¥12.61bnCN¥12.30bnCN¥9.43bnCN¥8.89bnCN¥8.12bnCN¥7.43bnCN¥6.89bnCN¥6.34bnCN¥5.40bn
Cash and short-term investmentsCN¥2.34bnCN¥2.74bnCN¥2.10bnCN¥1.98bnCN¥1.73bnCN¥1.81bnCN¥1.48bnCN¥1.20bnCN¥796.1mCN¥792.3m
Total liabilitiesCN¥4.83bnCN¥5.87bnCN¥4.34bnCN¥4.29bnCN¥3.95bnCN¥3.52bnCN¥3.10bnCN¥2.94bnCN¥2.56bnCN¥1.79bn
DebtCN¥2.11bnCN¥833.0mCN¥1.17bnCN¥1.14bnCN¥828.0mCN¥727.7mCN¥606.5mCN¥690.6mCN¥650.9mCN¥454.0m
Shareholders' equityCN¥5.36bnCN¥5.25bnCN¥6.56bnCN¥4.98bnCN¥4.78bnCN¥4.45bnCN¥4.20bnCN¥3.82bnCN¥3.67bnCN¥3.56bn
Shares outstanding798m743m773m724m756m761m760m714m777m788m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥289.2mCN¥808.1mCN¥754.3mCN¥253.9mCN¥251.6mCN¥409.9mCN¥429.5mCN¥352.1mCN¥242.5mCN¥311.2m
Capital spending−CN¥90.6m−CN¥79.4m−CN¥109.6m−CN¥101.7m−CN¥236.2m−CN¥158.7m−CN¥347.3m−CN¥217.3m−CN¥268.7m−CN¥203.5m
Free cash flowCN¥198.7mCN¥728.6mCN¥644.7mCN¥152.1mCN¥15.5mCN¥251.2mCN¥82.2mCN¥134.8m−CN¥26.2mCN¥107.7m
Dividends paid−CN¥227.1m−CN¥172.5m−CN¥146.6m−CN¥204.7m−CN¥203.6m−CN¥151.0m−CN¥75.9m−CN¥48.3m−CN¥163.7m−CN¥181.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥806.9mCN¥836.2mCN¥1.83bnCN¥1.40bnCN¥1.74bnCN¥1.61bnCN¥2.94bnCN¥2.01bn
Gross profitCN¥127.9mCN¥188.7m−CN¥1.42bnCN¥542.1mCN¥737.1mCN¥593.7mCN¥1.40bnCN¥881.9m
Operating income−CN¥96.3m−CN¥153.5mCN¥77.9mCN¥79.5mCN¥151.3mCN¥159.9mCN¥440.7mCN¥245.4m
Net income−CN¥222.2m−CN¥141.8mCN¥80.6mCN¥71.0mCN¥107.9mCN¥90.5mCN¥260.7mCN¥173.3m
Diluted earnings per share-0.28-0.180.100.090.140.110.350.23
Cash from operations——CN¥113.0m−CN¥16.0mCN¥358.0m−CN¥136.0mCN¥591.0mCN¥81.0m
Capital spending−CN¥13.0m−CN¥32.0m−CN¥32.0m−CN¥31.0m−CN¥13.0m−CN¥13.0m−CN¥48.0m−CN¥12.0m
Free cash flow——CN¥81.0m−CN¥47.0mCN¥345.0m−CN¥149.0mCN¥543.0mCN¥69.0m
Total assetsCN¥10.98bnCN¥11.22bnCN¥11.77bnCN¥12.01bnCN¥12.66bnCN¥12.70bnCN¥12.61bnCN¥10.02bn
Cash and short-term investments——CN¥2.34bnCN¥2.76bnCN¥3.08bnCN¥2.71bnCN¥2.74bnCN¥2.01bn
DebtCN¥690.2mCN¥693.5mCN¥2.06bnCN¥1.08bnCN¥1.52bnCN¥1.55bnCN¥704.1mCN¥682.2m
Shareholders' equityCN¥4.86bnCN¥5.22bnCN¥5.36bnCN¥5.31bnCN¥5.23bnCN¥5.35bnCN¥5.25bnCN¥5.53bn

Financial ratios

Data as of 8 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin38.5%43.2%46.1%41.4%41.1%42.9%
Operating margin7.2%11.5%9.6%6.3%8.2%7.5%
Net margin5.3%7.7%6.4%4.6%6.2%5.9%
Return on equity6.5%12.3%8.2%7.7%10.6%10.3%
Return on assets3.0%5.1%4.4%4.1%5.7%5.6%
Free cash flow yield5.8%14.6%13.7%6.0%7.9%9.1%
Revenue growth-21.7%-0.3%1.8%0.3%7.0%-5.0%
Earnings growth-46.0%19.9%41.1%-24.5%11.1%0.6%
Current ratio2.02x1.56x2.11x1.74x1.77x1.78x
Debt to equity0.38x0.15x0.13x0.22x0.16x0.38x
Equity ratio45.5%41.7%53.4%52.8%53.8%54.8%
Interest coverage8.93x33.50x41.72x11.06x16.15x15.44x
R&D as a share of sales1.6%1.3%1.1%0.8%1.2%1.7%
Buybacks as a share of market value-7.4%3.8%-6.8%4.3%0.6%-0.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-7.4%-3.1%3.0%
Operating income-1.6%-2.6%0.2%
Net income-3.0%-5.2%-1.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin41.2%42.5%42.3%43.1%
Operating margin9.4%8.5%8.1%7.9%
Net margin6.7%6.1%6.1%6.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings28.718.229.826.716.514.417.913.221.526.2
Price to sales1.51.41.91.21.00.81.00.61.22.1

Dividends and splits

Per share, in the currency the company pays

Paid for 7 years. Last went ex-dividend on 30 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.180.300.200.160.270.230.200.10
  • 2-for-1 split · 9 May 2016
  • 1-to-1 reverse split · 21 Mar 2006
  • 2-for-1 split · 18 Apr 2005
  • 8-for-5 split · 21 Jul 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.